Quick Answer
Allogene Therapeutics, Inc. reported Total Assets of $415.90 million for fiscal year 2025.
Allogene Therapeutics, Inc. Total Assets — Annual History
| Fiscal Year | Total Assets | YoY Change |
|---|---|---|
| 2025 | $415.90M | -24.2% |
| 2024 | $548.71M | -14.6% |
| 2023 | $642.84M | -9.9% |
| 2023 | $713.41M | -7.7% |
| 2023 | $773.01M | +3.1% |
| 2023 | $750.13M | -8.7% |
| 2022 | $821.58M | -8.1% |
| 2022 | $894.48M | -6.4% |
| 2022 | $955.62M | -2.3% |
| 2022 | $978.09M | -5.8% |
| 2021 | $1.04B | -15.4% |
| 2020 | $1.23B | +71.1% |
| 2019 | $717.80M | -7.2% |
| 2018 | $773.86M | — |
Quarterly Total Assets
| Quarter Ending | Total Assets | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $439.77M | -25.4% | -6.5% |
| June 30, 2025 | $470.59M | -27.3% | -7.4% |
| March 31, 2025 | $507.98M | -13.4% | -7.4% |
| December 31, 2024 | $548.71M | -14.6% | -6.9% |
| September 30, 2024 | $589.12M | -17.3% | -8.9% |
| June 30, 2024 | $646.88M | -16.1% | +10.3% |
| March 31, 2024 | $586.35M | -21.5% | -8.8% |
| December 31, 2023 | $642.84M | -21.3% | -9.8% |
- Allogene Therapeutics, Inc. showed a decrease of -24.2% in Total Assets compared to the prior fiscal year.
- Over the 2018–2025 period, Allogene Therapeutics, Inc.’s total assets has declined by 46.3% (from $773.86 million to $415.90 million).
- The most recent figure is from Allogene Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 12, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: